SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
31 May 2016
SkylineDx to Present New Data Demonstrating MMprofiler™ as Robust Prognostic Tool in Multiple Myeloma at the European Hematology Association 21st Annual Congress (EHA)
Studies Support Validity of SKY92 as a Superior Predictor of Risk Stratification in Newly Diagnosed and Relapsed Patients Rotterdam, the Netherlands and Laguna Hills, CA, May 31, 2016- SkylineDx today announced the presentation of four p...
Upcoming Events
06 Sep 2016 - 10 Sep 2016, Housten, Texas, USA
4th Annual Society of Hematologic Oncology (SOHO 2016)
15 Sep 2016 - 17 Sep 2016, Chicago
2016 ASH® Meeting on Hematologic Malignancies
30 Sep 2016 - 01 Oct 2016, New York, USA
NCCN Hematologic Malignancies